Femasys (NASDAQ:FEMY) Shares Up 4.5%

Femasys Inc. (NASDAQ:FEMY) shot up 4.5% during trading on Friday . The stock traded as high as $1.32 and last traded at $1.29. 62,294 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 590,263 shares. The stock had previously closed at $1.24.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. HC Wainwright boosted their target price on shares of Femasys from $10.00 to $12.00 and gave the company a “buy” rating in a report on Monday, April 1st. Chardan Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Femasys in a report on Monday, April 1st. Finally, Jonestrading increased their price target on Femasys from $7.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, March 20th.

Femasys Price Performance

The stock has a market capitalization of $28.51 million, a PE ratio of -1.40 and a beta of -2.76. The company has a current ratio of 7.59, a quick ratio of 7.37 and a debt-to-equity ratio of 0.24. The firm has a 50 day moving average price of $1.61 and a 200 day moving average price of $1.23.

Femasys (NASDAQ:FEMY) last released its earnings results on Thursday, March 28th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). Femasys had a negative net margin of 1,329.10% and a negative return on equity of 105.47%. The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.30 million. Research analysts anticipate that Femasys Inc. will post -0.88 earnings per share for the current year.

Institutional Trading of Femasys

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC purchased a new stake in shares of Femasys during the 3rd quarter worth approximately $295,000. Clear Creek Financial Management LLC boosted its stake in shares of Femasys by 30.6% during the 1st quarter. Clear Creek Financial Management LLC now owns 309,274 shares of the company’s stock worth $479,000 after purchasing an additional 72,505 shares during the period. Wealthspire Advisors LLC purchased a new stake in Femasys in the 3rd quarter worth about $84,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Femasys in the third quarter worth about $35,000. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.